PExA receives Horizon 2020 funding
The European Commission has selected PExAs project “BREATH: Biomarkers for Respiratory diseases detected in Exhaled Air through a new Technological instrument for research and Healthcare markets” for funding through the Research and Innovation Framework Program Horizon 2020.
The European Commission has selected PExAs projects for funding of a Phase 1 feasibility study through the "SME (Small Medium Enterprises) Instrument" call within EU’s Research and Innovation Framework Program Horizon 2020. Each project receives 50.000 Euro to carry out a feasibility study and to prepare a Phase 2 program which, if granted, could result in significant additional funding. A Phase 2 program, could be financed up to EUR 2.5 million by the European Commission.
The goal of the feasibility study is to define and optimize the technical strategy, focusing on new proprietary disposable products and new service functions that will facilitate the use of the instrument. An additional objective is to define a five-year plan for the second phase of commercialization, targeting hospitals and health care institutions.
The feasibility study is expected to be completed during the first half of 2017.
CEO Erik Ekbo comments
- We are very pleased to have been selected in competition with many other qualified companies and that the European Commission has decided to support this project financially. The focus is now on reaching the targets set for Phase 1 and to prepare for the Phase 2 program.
For further information, please contact:
Erik Ekbo, CEO
Phone: +46 723-92 30 30
E-mail: erik@pexa.se
This information is information which PExA AB is obligated to publish under the EU Market Abuse Regulation. The information was provided through the agency of above contact person, for publication on October 18, 2016.
PExA AB (556956-9246) develops and markets a research instrument with associated products and services to pulmonary researchers for easy and non-invasive sampling, in order to study respiratory diseases such as asthma and chronic obstructive pulmonary disease, COPD. Sampling with PExA can be used to detect lung diseases at an early stage. The sample can be compared to a "blood test for the small airways ". The aim is to facilitate the development of reliable and more individualized diagnosis, monitoring and treatment of respiratory diseases. The original idea and research behind the method comes from the unit for Occupational and Environmental Medicine at the Sahlgrenska Academy at Gothenburg University. Commercial operations started in 2010 with the support of GU Ventures incubator, and the company is founded by inventor, key employees, business angels and GU Ventures. The company's B-shares are listed on AktieTorget.